Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.68 |
| ▸ | DRD3 | P35462 | 8/20 | 0.68 |
| ▸ | DRD4 | P21917 | 6/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | DRD5 | P21918 | 1/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | HTR1D | P28221 | 1/20 | 0.64 |
| ▸ | HTR1B | P28222 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR1E | P28566 | 1/20 | 0.64 |
| ▸ | GPR183 | P32249 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10665994 | 0.97 | DRD2 (0.71) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL10668573 | 0.90 | DRD3 (0.71) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL13532794 | 0.89 | DRD2 (0.72) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL20029449 | 0.89 | DRD2 (0.71) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL7324533 | 0.89 | DRD2 (0.68) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL13532797 | 0.86 | DRD2 (0.87) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL10428538 | 0.86 | DRD2 (0.68) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL30193881 | 0.85 | DRD2 (0.66) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL30193630 | 0.85 | DRD2 (0.66) | DRD2DRD3DRD4SLC6A2SLC6A4 | |
| SCHEMBL23097707 | 0.84 | DRD3 (0.62) | DRD2DRD3DRD4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041774-A1 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-02-08 | — | — | US | disclosed |
| US-20220008341-A1 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-01-13 | — | — | US | disclosed |
| US-11154507-B2 | Freeze-dried aripiprazole formulation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-26 | — | — | US | disclosed |
| US-20170348308-A1 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATON AND METHOD | OTSUKA PHARMA CO LTD (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9763935-B2 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-19 | — | — | US | disclosed |
| EP-2717859-B1 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION | OTSUKA PHARMA CO LTD (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20150328335-A1 | ARIPIPRAZOLE COMPLEX FORUMLATION AND METHOD | OTSUKA PHARMA CO LTD (JP) | 2015-11-19 | — | — | US | disclosed |
| US-9066848-B2 | Process for making sterile aripiprazole of desired mean particle size | OTSUKA PHARMACEUTICALS CO., LTD. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-8999952-B2 | Aripiprazole complex formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8952013-B2 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8030313-B2 | Freeze dried formulation; 1 to 10 microns; water for injection; homogenous suspension releases aripiprazole over a period of at least one week; treating schizophrenia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20110166352-A1 | PROCESS FOR MAKING STERILE ARIPIPRAZOLE OF DESIRED MEAN PARTICLE SIZE | BRISTOL-MYERS SQUIBB COMPANY | 2011-07-07 | — | — | US | disclosed |
| US-20110160224-A1 | ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-30 | — | — | US | disclosed |
| US-7807680-B2 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090186903-A1 | ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-23 | — | — | US | disclosed |
| US-20080221121-A1 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-09-11 | — | — | US | disclosed |
| US-20080112986-A1 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-05-15 | — | — | US | disclosed |
| US-20080112985-A1 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-05-15 | — | — | US | disclosed |
| US-20080107745-A1 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-05-08 | — | — | US | disclosed |
| US-20050148597-A1 | Controlled release sterile injectable aripiprazole formulation and method | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008341-A1 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION | CYP2F1, CYP4F3, CYP2A6 | DRD2 302/4885DRD3 493/4885DRD4 196/4885 |
| US-20050148597-A1 | Controlled release sterile injectable aripiprazole formulation and method | CYP4F11, YIPF5, CYP4F8 | DRD2 1640/4885DRD3 2595/4885DRD4 2364/4885 |
| US-20080107745-A1 | Controlled release sterile injectable aripiprazole formulation and method | CYP4F11, YIPF5, CYP4F8 | DRD2 1640/4885DRD3 2595/4885DRD4 2364/4885 |
| US-20150328335-A1 | ARIPIPRAZOLE COMPLEX FORUMLATION AND METHOD | SBDS, CYP2C8, STS | DRD2 84/4885DRD3 360/4885DRD4 143/4885 |
| US-20110160224-A1 | ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD | SBDS, STS, SI | DRD2 107/4885DRD3 251/4885DRD4 137/4885 |
| US-20170348308-A1 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATON AND METHOD | CYP4F11, CYP4A11, CYP51A1 | DRD2 1812/4885DRD3 2886/4885DRD4 2775/4885 |
| US-20080112985-A1 | Controlled release sterile injectable aripiprazole formulation and method | CYP4F11, YIPF5, CYP4F8 | DRD2 1640/4885DRD3 2595/4885DRD4 2364/4885 |
| US-20110166352-A1 | PROCESS FOR MAKING STERILE ARIPIPRAZOLE OF DESIRED MEAN PARTICLE SIZE | CYP3A43, CYP2A6, CYP11A1 | DRD2 3163/4885DRD3 3238/4885DRD4 3200/4885 |
| US-11154507-B2 | Freeze-dried aripiprazole formulation | CYP2F1, CYP4F3, CYP2A6 | DRD2 302/4885DRD3 496/4885DRD4 201/4885 |
| US-20080112986-A1 | Controlled release sterile injectable aripiprazole formulation and method | CYP4F11, YIPF5, CYP4F8 | DRD2 1640/4885DRD3 2595/4885DRD4 2364/4885 |
| US-20090186903-A1 | ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD | SBDS, STS, SI | DRD2 107/4885DRD3 251/4885DRD4 137/4885 |
| US-20080221121-A1 | Controlled release sterile injectable aripiprazole formulation and method | CYP4F11, YIPF5, CYP4F8 | DRD2 1640/4885DRD3 2595/4885DRD4 2364/4885 |
| US-20240041774-A1 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION | CYP2F1, CYP4F3, CYP2A6 | DRD2 302/4885DRD3 493/4885DRD4 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.